Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Variant U1 Small Nuclear RNA 17 (RNVU1-17) is a non-coding RNA gene encoding a small nuclear RNA (snRNA) closely related to canonical U1 snRNA. It participates in pre-mRNA splicing, binding to the 5′ splice site and facilitating the assembly of the spliceosome complex in the nucleus[2][1]. Variant U1 snRNAs display high sequence similarity to canonical U1 snRNAs but may carry unique mutations or exist in variable copy numbers due to segmental duplications and genomic rearrangements[2]. The exact functionality of each variant (including RNVU1-17) may differ due to alterations in promoter or gene body sequences, with genome annotation updates potentially changing locus identification[2]. Although U1 snRNA family members are essential for cell viability and gene expression, variant loci like RNVU1-17 are not currently recognized as therapeutic targets or biomarkers, and their direct implication in disease is unclear. The assessment of mutations and copy number variation for these snRNAs presents technical challenges given their repetitive genomic context, especially for disease association studies[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Variant U1 Small Nuclear RNA 17 (RNVU1-17).